全文获取类型
收费全文 | 20532篇 |
免费 | 2054篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 274篇 |
儿科学 | 790篇 |
妇产科学 | 639篇 |
基础医学 | 2874篇 |
口腔科学 | 630篇 |
临床医学 | 2497篇 |
内科学 | 3814篇 |
皮肤病学 | 377篇 |
神经病学 | 1701篇 |
特种医学 | 876篇 |
外科学 | 2400篇 |
综合类 | 631篇 |
一般理论 | 9篇 |
预防医学 | 2085篇 |
眼科学 | 289篇 |
药学 | 1592篇 |
1篇 | |
中国医学 | 97篇 |
肿瘤学 | 1045篇 |
出版年
2021年 | 301篇 |
2020年 | 184篇 |
2019年 | 290篇 |
2018年 | 354篇 |
2017年 | 281篇 |
2016年 | 299篇 |
2015年 | 342篇 |
2014年 | 476篇 |
2013年 | 667篇 |
2012年 | 837篇 |
2011年 | 862篇 |
2010年 | 582篇 |
2009年 | 489篇 |
2008年 | 876篇 |
2007年 | 853篇 |
2006年 | 889篇 |
2005年 | 741篇 |
2004年 | 726篇 |
2003年 | 662篇 |
2002年 | 674篇 |
2001年 | 644篇 |
2000年 | 663篇 |
1999年 | 548篇 |
1998年 | 297篇 |
1997年 | 248篇 |
1996年 | 264篇 |
1995年 | 249篇 |
1994年 | 237篇 |
1993年 | 249篇 |
1992年 | 466篇 |
1991年 | 440篇 |
1990年 | 437篇 |
1989年 | 468篇 |
1988年 | 456篇 |
1987年 | 368篇 |
1986年 | 382篇 |
1985年 | 407篇 |
1984年 | 283篇 |
1983年 | 232篇 |
1982年 | 174篇 |
1981年 | 187篇 |
1979年 | 216篇 |
1978年 | 194篇 |
1977年 | 211篇 |
1976年 | 178篇 |
1975年 | 173篇 |
1974年 | 175篇 |
1973年 | 183篇 |
1972年 | 170篇 |
1971年 | 166篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
White TO Robinson CM 《The Journal of bone and joint surgery. British volume》2002,84(7):1084; author reply 1084-1084; author reply 1085
992.
Bridging a peripheral nerve defect using collagen filaments 总被引:1,自引:0,他引:1
Meek MF Robinson PH Coert JH 《The Journal of hand surgery》2002,27(2):361; author reply 361-361; author reply 362
993.
Effect of technique on intraocular pressure after combined cataract and glaucoma surgery: An evidence-based review 总被引:3,自引:0,他引:3
Jampel HD Friedman DS Lubomski LH Kempen JH Quigley H Congdon N Levkovitch-Verbin H Robinson KA Bass EB 《Ophthalmology》2002,109(12):48-24; quiz 2225, 2231
TOPIC: To analyze the literature pertaining to the techniques used in combined cataract and glaucoma surgery, including the technique of cataract extraction, the timing of the surgery (staged procedure versus combined procedure), the anatomic location of the operation, and the use of antifibrosis agents. CLINICAL RELEVANCE: Cataract and glaucoma are both common conditions and are often present in the same patient. There is no agreement concerning the optimal surgical management of these disorders when they coexist. METHODS/LITERATURE REVIEWED: Electronic searches of English language articles published since 1964 were conducted in Pub MED and CENTRAL, the Cochrane Collaboration's database. These were augmented by a hand search of six ophthalmology journals and the reference lists of a sample of studies included in the literature review. Evidence grades (A, strong; B, moderate; C, weak; I, insufficient) were assigned to the evidence that involved a direct comparison of alternative techniques. RESULTS: The preponderance of evidence from the literature suggests a small (2-4 mmHg) benefit from the use of mitomycin-C (MMC), but not 5-fluorouracil (5-FU), in combined cataract and glaucoma surgery (evidence grade B). Two-site surgery provides slightly lower (1-3 mmHg) intraocular pressure (IOP) than one-site surgery (evidence grade C), and IOP is lowered more (1-3 mmHg) by phacoemulsification than by nuclear expression in combined procedures (evidence grade C). There is insufficient evidence to conclude either that staged or combined procedures give better results or that alternative glaucoma procedures are superior to trabeculectomy in combined procedures. CONCLUSIONS: In the literature on surgical techniques and adjuvants used in the management of coexisting cataract and glaucoma, the strongest evidence of efficacy exists for using MMC, separating the incisions for cataract and glaucoma surgery, and removing the nucleus by phacoemulsification. 相似文献
994.
995.
996.
997.
998.
Robinson M Fitzgerald S Hegedus R Murthy A Jokubaitis L;FAST Trial Investigators 《Alimentary pharmacology & therapeutics》2002,16(3):445-454
BACKGROUND: In numerous clinical trials, proton pump inhibitors have demonstrated potent acid suppression and healing of erosive oesophagitis, as well as successful symptom relief for the entire spectrum of gastro-oesophageal reflux disease. AIM: The 'Future of Acid Suppression Therapy' (FAST) trial evaluated, in actual clinical practice, the timing of symptom relief, changes in symptom severity, health-related quality of life and safety in endoscopically confirmed erosive gastro-oesophageal reflux disease treated with rabeprazole. METHODS: This open-label, multicentre study enrolled 2579 patients to receive rabeprazole treatment using 20 mg once daily for 8 weeks. Between two clinical visits (at enrollment and week 8), patients used an interactive voice response system to rate gastro-oesophageal reflux disease symptoms. Subgroup analyses of efficacy were conducted for gender, age, Hetzel-Dent grade, presence of Barrett's oesophagus and for patients reporting previously ineffective symptom relief with omeprazole or lansoprazole. RESULTS: On day 1, rabeprazole significantly decreased daytime and night-time heartburn severity, regurgitation and belching. Complete relief of daytime and night-time heartburn was achieved in 64.0% and 69.2% of symptomatic patients, respectively, on day 1, and in 81.1% and 85.7% of patients, respectively, on day 7. Patients with moderate or severe heartburn symptoms at baseline achieved an even greater degree of satisfactory symptom relief (none or mild) from day 1 onwards. The median time to satisfactory heartburn relief was 2 days. Subgroup analyses showed no consistent differences in efficacy compared to the overall population treated. Health-related quality of life in patients was significantly lower than that of the US general population and improved significantly after 8 weeks of rabeprazole therapy. Rabeprazole was well tolerated, with headache as the most common adverse event, reported by less than 2% of the study population. CONCLUSIONS: In this large, open-label trial, rabeprazole rapidly and effectively relieved gastro-oesophageal reflux disease symptoms in most patients with erosive oesophagitis. Substantial symptom relief was noted on day 1; improvement continued over the first week and at week 4. By week 8, the health-related quality of life had also improved vs. baseline. 相似文献
999.
Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine 总被引:4,自引:0,他引:4
Fraser AG Orchard TR Robinson EM Jewell DP 《Alimentary pharmacology & therapeutics》2002,16(7):1225-1232
BACKGROUND AND AIM: Data from renal transplant and rheumatoid arthritis patients suggest that there is an increased risk of malignancy after treatment with azathioprine. Whether this is true for patients with inflammatory bowel disease remains uncertain. METHOD: A retrospective review of clinical notes was performed. RESULTS: Azathioprine was given to 626 of 2204 patients (855 with Crohn's disease and 1349 with ulcerative colitis). The mean total duration of azathioprine use was 27 months. The mean follow-up from diagnosis was 13.7 years and the mean follow-up from the start of azathioprine treatment was 6.9 years. Thirty-one cancers were observed in 30 patients treated with azathioprine (4.5%) and 77 cancers were observed in 70 patients not treated with azathioprine (4.5%; P=N.S.). Logistic regression analysis (including in the model the age, sex, diagnosis and extent of disease) showed that treatment with azathioprine did not significantly affect the risk of the development of cancer. Eight patients had lymphoma; three had been given azathioprine (P=N.S.). For patients with ulcerative colitis, the number of colorectal cancers (including high-grade dysplasia) in patients given azathioprine was eight of 355 (2.2%), compared with 28 of 994 (2.8%) for patients not given azathioprine (P=N.S.). The cumulative risk of colorectal cancer or dysplasia/dysplasia-associated lesion or mass (adjusted to exclude post-colectomy patients) after 10, 20, 30 and 40 years of ulcerative colitis was 0.4%, 1.3%, 9%and 15.5%, respectively. CONCLUSION: No increased risk of cancer diagnosis following azathioprine treatment was observed. 相似文献
1000.
Comparison of low doses of aged and freshly fractured silica on pulmonary inflammation and damage in the rat 总被引:3,自引:0,他引:3
Most previous studies of silica toxicity have used relatively high exposure doses of silica. In this study, male rats received by intratracheal instillation either vehicle, aged or freshly fractured silica at a dose of either 5 microg/rat once a week for 12 weeks (total dose=60 microg) or 20 microg/rat once a week for 12 weeks (total dose=240 microg). One week after the last exposure, bronchoalveolar lavage (BAL) was conducted and markers of pulmonary inflammation, alveolar macrophage (AM) activation and pulmonary damage were examined. For rats exposed to a total of 60 microg silica, both aged and freshly fractured silica increased polymorphonuclear leukocytes (PMN) yield and AM activation above control to a similar degree, but no evidence of pulmonary damage, as measured by BAL fluid lactate dehydrogenase activity or albumin concentration, was detected. For rats exposed to 240 microg silica, aged or freshly fractured silica increased PMN yield and AM activation above control. However, zymosan-stimulated and L-NAME sensitive AM chemiluminescence was greater for rats exposed to freshly fractured silica compared to aged silica. Exposure to 240 microg aged or freshly fractured silica also resulted in pulmonary damage, but the extent of this damage did not differ between the two types of silica. The results suggest that exposure of rats to silica levels far lower than those previously examined can cause pulmonary inflammation. In addition, exposure to freshly fractured silica causes greater generation of reactive oxygen species from AM, measured as AM chemiluminescence, in comparison to aged silica, but there is an apparent threshold below which this difference does not occur. 相似文献